



JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015,
Haryana (India)

Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com
CIN NO. L74899DL1978PLC009181

February 02, 2024

The Department of Corporate Services-Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services-Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
--	---

Subject: Intimation under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR)

Dear Sir/ Madam,

We wish to inform you that consequent to the appointment of Mr. Ashish Lakhotia as Chief Financial Officer, the Board of Directors have approved changes in KMPs authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s) under the SEBI LODR. The contact details of the KMPs authorized is as under:

Name of KMP	Designation	Contact details
Mr. Manish Gupta	Managing Director	Tel No. 0124 - 4406710 Email id: cs@jagsonpal.com
Mr. Ashish Lakhotia	Chief Financial Officer	
Mr. Abhishek Joshi	Company Secretary	

We request you to take the above on record.

Thanking you,

For **Jagsonpal Pharmaceuticals Limited**

Abhishek Joshi
Company Secretary and Compliance Officer

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110049 (India)